McKesson's Revenue Miss Is a Mirage

McKesson's fiscal 2026 performance was highlighted by 12% revenue growth and 18% adjusted EPS growth, exceeding long-range growth targets and demonstrating the company's ability to consistently deliver growth and operating leverage across the enterprise. The company reported record revenue of $97.8 billion in the first quarter of fiscal 2026, representing 23% growth compared to the previous year. This growth was primarily driven by the U.S. Pharmaceutical segment due to increased prescription volumes from retail national account customers and growth in the distribution of oncology and specialty products. McKesson's strategic focus on expanding specialty provider support and accelerating patient access through scaled and integrated biopharma support services has been instrumental in driving performance. The company remains committed to executing with discipline across its portfolio, investing in high-growth and high-margin areas in Oncology and Biopharma Services to deliver sustainable growth and create long-term value for shareholders.

McKesson's stock has declined roughly 23% from its 52-week high of $999, closing at $766.08 on May 22, 2026. The decline gathered momentum around the Q4 earnings release on May 7, which showed a revenue shortfall: quarterly revenue of $96.3 billion missed the $101.35 billion consensus expectation, even as adjusted EPS of $11.69 edged past the $11.56 consensus.

The market's disappointment over that top-line miss obscures a more important signal: McKesson's earnings engine is operating at full capacity. Full-year adjusted EPS of $39.11 grew 18%, exceeding the company's own 12–18% long-range growth framework. Adjusted operating profit rose 15% to $6.5 billion. The disconnect between revenue optics and profit reality is the core of the opportunity.

Why Revenue Is a Noisy Signal

Investors who anchor on McKesson's top line are watching the wrong metric. The pharmaceutical distribution business — roughly 83% of consolidated revenue — operates primarily on a fee-for-service model. McKesson earns fees based on the volume of products distributed and services rendered, not on the...